

REMARKS

Claims 1-4 and 6-8 are pending and claims 5 and 9 stand cancelled.

A telephonic interview with Examiner Pryor was held on March 27, 2007. The Examiner is thanked for his helpful comments during the interview. In accord with his suggestions, Claim 6 has been amended to delete recitation of the disorders to be treated, which are not necessary for patentability. Support for this amendment can be found throughout the specification. No new matter is presented by this amendment.

During the interview, the Examiner was presented the structures of various compounds presented in the specification by name as evidence of support for the previously presented amendments. Those structures are reproduced below. Reconsideration of the application is requested in view of the remarks which follow.


Claims 1-4 and 6-8 stand rejected under 35 USC 112, 1st paragraph, as allegedly failing to comply with the written description requirement. In particular, the Examiner alleges that there was insufficient support for the amendments concerning R⁴ and R⁶. The rejection is respectfully traversed.

As previously discussed, ample written description and support for the subject matter recited in claims 1-4 and 6-8 appears in the present application. The Examiner appears to be requiring exact language in the specification to support the claim language. This is not the proper standard. Indeed, the "specification need not describe the claimed invention in *ipsis verbis* to comply with the written description requirement." *Ex parte Sorenson*, 3 U.S.P.Q.2d 1462, 1463 (Bd. Pat. App. & Interf. 1987).

To that end, Applicants respectfully highlight the following exemplary compounds, which provide support for the claims as presented.


For instance, compounds of Formula (1) wherein R_4 is H, and one or two of R_5 , R_6 and R_8 each represent halogen, lower alkyl or lower alkoxy are demonstrated as:

Examples 5 and 6: (Page 19 of the specification)




4-(4-methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide and
4-(4-methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate (respectfully);

Examples 7 and 8: (Page 20 of the specification):




4-(4-methylpiperazin-1-ylaminomethyl)-N-[2-methyl-5-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide and
4-(4-methylpiperazin-1-ylaminomethyl)-N-[2-methyl-5-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate (respectfully);

Example 24: (Page 32, lines 23-29 of the specification)



4-(4-methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate; and


Example 28: (Page 34, lines 21-22 of the specification)



4-(4-methylpiperazin-1-ylaminomethyl)-N-[2-fluoro-5-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate.


Additionally, compounds of Formula I wherein R₄ is methyl, and R₅, R₆ and R₈ is H are demonstrated as:

Example 2: (Page 16, lines 1-12 of the specification)



4-(4-methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate; and


Example 4: (Page 16, line 30 through Page 17, line 10 of the specification)



4-(4-methylpiperazin-1-ylaminomethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate.


Further, compounds of Formula I wherein R_4 is methoxy, and R_5 , R_6 and R_8 are H are demonstrated as:

Example 20: (Page 29, line 30 through Page 30, line 9 of the specification)



4-(4-methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate; and

Example 22: (Page 30, lines 23-29 of the specification)




4-(4-methylpiperazin-1-ylaminomethyl)-N-[4-methoxy-3-(4-(pyridin-3-yl)pyrimidin-2-yl)aminophenyl]benzamide methanesulfonate.

Accordingly, the claims are fully compliant with the requirements of 35 USC 112, 1st paragraph, including the written description requirement. Reconsideration and withdrawal of the rejection are respectfully requested.

In view of the above remarks, Applicant believes the pending application is in condition for immediate allowance.

Dated: April 4, 2007

Respectfully submitted,

By 

Nicholas J. DiCeglie, Jr.

Registration No.: 51,615

Christine C. O'Day

Registration No.: 38,256

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant